Drug Profile


Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Quintiles; Zhejiang University
  • Class Aminopyridines; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Apoptosis stimulants; CD244 antigen modulators; CD8 positive T lymphocyte stimulants; Histone deacetylase inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase III Breast cancer
  • Phase II/III Cutaneous T cell lymphoma; HIV infections
  • Phase II Adult T-cell leukaemia-lymphoma; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Jun 2017 Efficacy, safety and pharmacokinetics data from a phase III trial in Breast cancer presented at 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 19 Apr 2017 GNT Biotech & Medicals Corporation intends to submit a NDA application for Breast cancer in Taiwan in 2019
  • 19 Apr 2017 The Taiwan Food and Drug Administration approves IND application for tucidinostat in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top